Prevention strategies of cervical cancer in the HPV vaccine era

被引：47

作者：

Bosch, Xavier

Harper, Diane

机构：

[1] Hosp Llobregat, Inst Catala Oncol, Epidemiol & Canc Registrat Unit, Barcelona 70890, Spain

[2] Dartmouth Med Sch, Dept Family & Community Med, Dept Obstet & Gynecol, Hanover, NH USA

来源：

GYNECOLOGIC ONCOLOGY | 2006年 / 103卷 / 01期

关键词：

cervical cancer; prevention; screening; vaccine; HPV; prophylactic; PAP smear;

D O I：

10.1016/j.ygyno.2006.07.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：21 / 24

页数：4

共 9 条

[1]

[Anonymous], 2005, IARC HDB CANC PREV C

[2] A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine [J].

Ault, KA ;

Giuliano, AR ;

Edwards, RP ;

Tamms, G ;

Kim, LL ;

Smith, JF ;

Jansen, KU ;

Allende, M ;

Taddeo, FJ ;

Skulsky, DM ;

Barr, E .

VACCINE, 2004, 22 (23-24) :3004-3007

[3] Overview of the European and North American studies on HPV testing in primary cervical cancer screening [J].

Cuzick, Jack ;

Clavel, Christine ;

Petry, Karl-Ulrich ;

Meijer, Chris J. L. M. ;

Hoyer, Heike ;

Ratnam, Samuel ;

Szarewski, Anne ;

Birembaut, Philippe ;

Kulasingam, Shalini ;

Sasieni, Peter ;

Iftner, Thomas .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) :1095-1101

[4] Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women [J].

Fife, KH ;

Wheeler, CM ;

Koutsky, LA ;

Barr, E ;

Brown, DR ;

Schiff, MA ;

Kiviat, NB ;

Jansen, KU ;

Barber, H ;

Smith, JF ;

Tadesse, A ;

Giacoletti, K ;

Smith, PR ;

Suhr, G ;

Johnson, DA .

VACCINE, 2004, 22 (21-22) :2943-2952

[5] Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [J].

Harper, DM ;

Franco, EL ;

Wheeler, C ;

Ferris, DG ;

Jenkins, D ;

Schuind, A ;

Zahaf, T ;

Innis, B ;

Naud, P ;

De Carvalho, NS ;

Roteli-Martins, CM ;

Teixeira, J ;

Blatter, MM ;

Korn, AP ;

Quint, W ;

Dubin, G .

LANCET, 2004, 364 (9447) :1757-1765

[6] Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial [J].

Harper, DM ;

Franco, EL ;

Wheeler, CM ;

Moscicki, AB ;

Romonowski, B ;

Roteli-Martins, CM ;

Jenkins, D ;

Schuind, A ;

Clemens, SAC ;

Dubin, G .

LANCET, 2006, 367 (9518) :1247-1255

[7] A controlled trial of a human papillomavirus type 16 vaccine [J].

Koutsky, LA ;

Ault, KA ;

Wheeler, CM ;

Brown, DR ;

Barr, E ;

Alvarez, FB ;

Chiacchierini, LM ;

Jansen, KU .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651

[8] Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 L1 capsomers [J].

Orozco, JJ ;

Carter, JJ ;

Koutsky, LA ;

Galloway, DA .

JOURNAL OF VIROLOGY, 2005, 79 (15) :9503-9514

[9] Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial [J].

Villa, LL ;

Costa, RLR ;

Petta, CA ;

Andrade, RP ;

Ault, KA ;

Giuliano, AR ;

Wheeler, CM ;

Koutsky, LA ;

Malm, C ;

Lehtinen, M ;

Skjeldestad, FE ;

Olsson, SE ;

Steinwall, M ;

Brown, DR ;

Kurman, R ;

Ronnett, BM ;

Stoler, MH ;

Ferenczy, A ;

Harper, DM ;

Tamms, GM ;

Yu, J ;

Lupinacci, L ;

Railkar, R ;

Taddeo, FJ ;

Jansen, KU ;

Esser, MT ;

Sings, HL ;

Saah, AJ ;

Lupinacci, L .

LANCET ONCOLOGY, 2005, 6 (05) :271-278

← 1 →